Media.Player

MicroRNA expression profiles for diagnosis and microRNA based therapeutics for Alzheimer's disease and related dementias

總結

John F. Crary, M.D., Ph.D..

技術優勢

Could guide development of a highly targeted therapyPotential therapy may have minimal side effects, as microRNAs target specific genes for regulationPersistent synthetic microRNAs can be delivered to specific brain regions to avoid off-target effects in other tissuesPatent information:Tech Ventures Reference: IR CU12162

技術應用

Identifies gene expression changes that confer risk for neurodegeneration Targeted synthetic microRNAs for treatment of neurodegenerationNovel in vitro assays for drug screens that target tau expresssionNovel transgenic animals for drug screens that target tau expressionGenetic markers for Alzheimer's disease diagnosisGenetic markers for assessing an individual's risk for development of age-related tauopathy

詳細技術說明

John F. Crary, M.D., Ph.D..

*Abstract

None

*Inquiry

Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU12162

*Principal Investigation

*Publications

I. Santa-Maria, A. Haggiagi, XM Liu, J. Wasserscheid, P. T. Nelson, K. Dewar, L.N. Clark, J. F. Crary. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol, Nov;124(5):693-704.

國家/地區

美國